

**Listing of claims**

This listing of claims will replace all prior versions and listings of the claims in the application.

Claims 1-5 (cancelled)

Claim 6. (currently amended) The method of claim [19] 23, wherein the composition is administered in a form of a cream, a gel, a gelatin capsule or a patch.

Claim 7. (currently amended) The method of claim [19] 23, wherein the at least one 12-HETE further comprises 12(R)-HETE.

Claim 8. (currently amended) The method of claim [19] 23, wherein the at least one 12-HETE further comprises 12(S)-HETE.

Claims 9-10 (cancelled)

Claim 11. (currently amended) The method of claim [20] 24, wherein the composition is administered in a form of a cream, a gel, a gelatin capsule or a patch.

Claims 12-13 (cancelled)

Claims 14-18 (withdrawn)

Claims 19-20. (cancelled)

Claim 21. (currently amended) The method of claim ~~20~~ 24, wherein the metabolite comprises 12(R)-HETE.

Claim 22. (currently amended) The method of claim ~~20~~ 24, wherein the metabolite comprises 12(S)-HETE.

Claim 23. (New) A method of inhibiting differentiation of a fibroblast to an adipocyte comprising administering to a human or an animal either as a nutraceutical formulation or topically on the areas concerned by localized excess subcutaneous fat deposits an effective amount of a composition comprising at least one of 12-hydroxyeicosatetraenoic acid or 12-HETE and 11,12-epoxyeicosatetraenoic acid or 11,12-EET.

Claim 24. (New) A method of inhibiting differentiation of a fibroblast to an adipocyte comprising administering to a human or an animal either as a nutraceutical formulation or topically on the areas concerned by localized excess subcutaneous fat deposits an effective amount of a composition comprising an arachidonic oxidation cascade metabolite, wherein the metabolite is the stereoisomer S of 12-hydroxyeicosatetraenoic acid or 12(S)-HETE,

the stereoisomer R of 12-hydroxyecosatetraenoic acid or 12(R)-HETE, the 11,12-hydroxyecosatriaenoic acid or the 11,12-EET.